Barry Michael Fine, MD, PHD Specialties: Cardiovascular Disease, Internal Medicine
Please contact the doctor's office to verify that your insurance is accepted.
- Empire Blue Cross/Blue Shield
- Local 1199
- Magnacare (National)
- MVP Health Care
- Oxford Health Plans
About Barry Michael Fine, MD, PHD
Barry Fine MD PhD is physician scientist whose lab focuses stem cells and engineered human cardiac microtissues to model cardiac disease and develop novel translational therapies. He is a attending on the inpatient cardiology consult service and is board certified in Internal Medicine, Cardiovascular Diseases and Echocardiography.
Dr. Fine is an Assistant Professor of Medicine in Cardiology at Columbia University Medical Center, College of Physicians and Surgeons and attending cardiologist at New York Presbyterian Hospital. He completed the MD PhD Medical Scientist Training Program in 2009 at Columbia University. His graduate work centered on signal transduction pathways involving PI3K and secreted phosphatases in cancer and diabetes. Following this, he entered the ABIM Research Pathway and completed both Internal Medicine Residency and Cardiology Fellowship at New York Hospital - Columbia University Medical Center. He then acquired post-doctoral training in biomedical engineering with University Professor and National Academy Member Gordana Vunjak-Novakovic under an NIH T32 Training Grant.
The goal of his research is to leverage advances in biomedical engineering and genetic manipulation to improve modeling cardiac diseases. His current laboratory focuses on utilizing human cardiomyocytes derived from induced pluripotent stem cells to three aspects of cardiac biology and disease: 1) understanding metabolic determinants of human cardiomyocyte survival and contractility utilizing engineered human tissues, 2) modeling congenital heart disease using programmed differentiation of stem cells to cardiomyocytes and CRISPR to mimic inherited mutations found in a specific disease called heterotaxy and 3) identifying determinants and biomarkers of graft failure after heart transplant using exosome proteomics and machine learning.
- NewYork-Presbyterian / Columbia University Irving Medical Center
- Cardiovascular Disease
- Internal Medicine